On October 1, 2025 Jecho Biopharmaceuticals Co., Ltd. (hereinafter referred to as "Jechobio") reported it has made another breakthrough in independently developed innovative drugs, offering a tribute to the National Day through scientific achievement (Press release, Jecho Laboratories, OCT 1, 2025, View Source [SID1234656380]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jechobio has received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration (NMPA), officially approving the clinical trial of JL19001 injection for the treatment of non-muscle-invasive bladder cancer (NMIBC).

Looking ahead, Jechobio will continue to uphold its innovation-driven mission, accelerate its drug development efforts, and contribute to advancing human health and well-being worldwide.

About JL19001 Injection

JL19001 injection is a Class I innovative drug jointly developed by Jecho laboratories, Inc. (USA) and Jecho Biopharmaceuticals Co., Ltd. It is a fusion protein composed of recombinant human serum albumin (HSA) and an IL-15Rα/IL-15 complex, designed to activate NK cells and CD8⁺ T cells, enhancing both innate and adaptive immune responses.

When used in combination with Bacillus Calmette–Guérin (BCG), JL19001 is intended to treat non-muscle-invasive bladder cancer (NMIBC) by helping avoid bladder removal surgery, thus improving patient survival rates and quality of life.